Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M179,092Revenue $M44,033Net Margin (%)12.5Z-Score3.2
Enterprise Value $M192,722EPS $1.5Operating Margin %14.5F-Score6
P/E(ttm))34.4Cash Flow Per Share $6.3Pre-tax Margin (%)15.6Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %3.1Quick Ratio1.1Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %-6.3Current Ratio1.3Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %13.3ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)11.2Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,851ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 62.827%Add 323%536,550
MRKRay Dalio 2014-09-30 Buy 0.01%$55.64 - $61.18
($58.89)
$ 62.827%New holding, 14141 sh.14,141
MRKJean-Marie Eveillard 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 62.827%Reduce -38.25%1,083,826
MRKGeorge Soros 2014-09-30 Sold Out -0.04%$55.64 - $61.18
($58.89)
$ 62.827%Sold Out0
MRKKen Fisher 2014-06-30 Add0.7%$54.83 - $59.62
($57.16)
$ 62.8210%Add 791.55%6,464,243
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 62.8210%Add 3456.04%126,844
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 62.8210%New holding, 86800 sh.86,800
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 62.8210%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 62.8210%Reduce -10.01%35,960,137
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 62.8210%Reduce -21.54%1,755,082
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 62.8210%Sold Out0
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 62.8216%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 62.8216%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 62.8216%New holding, 3567 sh.3,567
MRKIrving Kahn 2014-03-31 Reduce-2.88%$49.49 - $57.47
($54)
$ 62.8216%Reduce -55.32%1,128,415
MRKBill Nygren 2014-03-31 Sold Out -0.69%$49.49 - $57.47
($54.09)
$ 62.8216%Sold Out0
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 62.8216%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 62.8216%Reduce -18.11%39,959,196
MRKHOTCHKIS & WILEY 2014-03-31 Sold Out -0.22%$49.49 - $57.47
($54.09)
$ 62.8216%Sold Out0
MRKVanguard Health Care Fund 2014-03-31 Reduce-0.15%$49.49 - $57.47
($54)
$ 62.8216%Reduce -2.58%35,616,848
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK Brian Rogers 2014-12-316,625,7000.231.4
MRK Ray Dalio 2014-09-3014,14100.01New Buy
MRK Joel Greenblatt 2014-09-30536,5500.020.32+323%
MRK Ruane Cunniff 2014-09-304,78400+3.8%
MRK Mario Gabelli 2014-09-30162,7060.010.05+1.49%
MRK Robert Bruce 2014-09-30265,0000.014.3+1.34%
MRK Ken Fisher 2014-09-306,533,4750.230.83+1.07%
MRK Prem Watsa 2014-09-3012,00000.05
MRK James Barrow 2014-09-3022,769,0880.81.8-0.11%
MRK NWQ Managers 2014-09-3083,81100.06-0.59%
MRK Richard Snow 2014-09-305,37500.01-0.65%
MRK Irving Kahn 2014-09-301,109,1890.0410.7-0.97%
MRK Vanguard Health Care Fund 2014-09-3033,420,7481.175.1-1.38%
MRK Dodge & Cox 2014-09-3035,057,6681.232-2.51%
MRK Charles Brandes 2014-09-302,320,2880.081.8-4.69%
MRK Jean-Marie Eveillard 2014-09-301,083,8260.040.16-38.25%
MRK George Soros 2014-09-30000Sold Out
MRK Mark Hillman 2013-12-3117,80701.3
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.480.54view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.470.56view
FRAZIER KENNETH CChairman, President & CEO 2014-12-10Sell9,846$604.7view
Kuhlik Bruce NExe V-P & Gen Counsel 2014-12-08Sell50,000$621.32view
LAZARUS ROCHELLE BDirector 2014-11-26Sell10,000$59.635.35view
WEEKS WENDELL PDirector 2014-11-24Sell5,000$59.136.24view
FRAZIER KENNETH CChairman, President & CEO 2014-11-10Sell10,000$57.988.35view
FRAZIER KENNETH CChairman, President & CEO 2014-10-10Sell9,895$59.735.17view
FRAZIER KENNETH CChairman, President & CEO 2014-09-10Sell9,814$60.483.87view
Schechter Adam HEVP & Pres-Global Human Health 2014-08-25Sell22,000$59.75.23view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      World Economic Forum 2015 – What To Look Forward For Jan 18 2015 
      Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
      Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
      T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
      You Should Hold Merck According to Dividends Generation Nov 21 2014 
      Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
      A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Dividend Aristocrats In Focus Parts 30: Sigma-Aldrich Oct 28 2014 
      What is Abner Herrman Investing In? Oct 16 2014 

      More From Other Websites
      Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog Jan 26 2015
      Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid... Jan 26 2015
      8:30 am Merck announces CHMP issues positive opinion for investigational antibiotic SIVEXTRO Jan 26 2015
      Merck Completes Tender Offer to Acquire Cubist Jan 26 2015
      Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for... Jan 26 2015
      First GSK Ebola vaccine shipment due to arrive in Liberia Jan 23 2015
      Dogs of the Dow can sniff out income Jan 23 2015
      Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for... Jan 22 2015
      Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Jan 22 2015
      We are funding part of ACA: Novartis CEO Jan 22 2015
      Merck Insiders' Planned Sales Hit $5.2 Million Jan 21 2015
      Merck Will No Longer Sell its Victrelis Hepatitis C Drug in the U.S. Jan 21 2015
      Merck Completes Tender Offer to Acquire Cubist Jan 21 2015
      p53, Immunology and Antibody Drug Conjugate Therapies Bringing More Powerful Weapons to Battlefield... Jan 21 2015
      Dana Holding Set to Join the S&P MidCap 400 Jan 20 2015
      Bristol-Myers Names New CEO Jan 20 2015
      Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog Jan 20 2015
      Merck's 'not up for a big deal in 2015': Chair Jan 20 2015
      6 Ways to Trade Merck this Week Jan 20 2015
      Merck KGaA Presents Liquid Crystal Window Technology at BAU 2015 Jan 20 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK